Valneva provides updated 2023 financial guidance

Saint-herblain (france), december 29, 2023 – valneva se (nasdaq: valn; euronext paris: vla), a specialty vaccine company, today announced that the company is modifying its financial guidance for 2023. product sales guidance remains unchanged, as do anticipated r&d expenses. the €90 million to €110 million of other income related to proceeds from potential sale of the company's priority review voucher (prv), which was previously expected before year-end, is now expected in early 2024.
VALN Ratings Summary
VALN Quant Ranking